JACIFUSEN Trademark

Trademark Overview

On Thursday, March 12, 2026, a trademark application was filed for JACIFUSEN with the United States Patent and Trademark Office. The USPTO has given the JACIFUSEN trademark a serial number of 79449551. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, May 7, 2026. This trademark is owned by Otsuka Pharmaceutical Co., Ltd.. The JACIFUSEN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS)
jacifusen

General Information

Serial Number79449551
Word MarkJACIFUSEN
Filing DateThursday, March 12, 2026
Status630 - NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER
Status DateThursday, May 7, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing0 - NOT AVAILABLE
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS)

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, June 1, 2026
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameOtsuka Pharmaceutical Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events

Event DateEvent Description
Thursday, May 7, 2026SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, June 1, 2026LIMITATION FROM ORIGINAL APPLICATION ENTERED

Related Keywords

jacifusen treatment preparations pharmaceutical amyotrophic sclerosis disorders lateral system central nervous